Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00417183|
Recruitment Status : Unknown
Verified December 2006 by Eugonia.
Recruitment status was: Recruiting
First Posted : December 29, 2006
Last Update Posted : December 29, 2006
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: Arvekap 0.1 mg (Triptorelin, Ipsen, France) Drug: Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)||Phase 4|
The formulation of controlled ovarian stimulation protocols is one of the primary reasons for the successful development of IVF. The "long" GnRH agonist protocol, also known as the gold standard, has been widely used with considerable success. More recently, on the other hand, GnRH antagonist provide a new promising approach for endogenous gonadotrophin suppression by blocking the GnRH receptor. There is conflicting data in the literature regarding the relative merits of the two ovarian stimulation protocols.
COMPARISON: Pregnancy rates and embryological data will by assessed in IVF patients treated with either the "long" GnRH agonist (Arvekap) or the flexible GnRH antagonist (Ganirelix) protocol.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders|
|Study Start Date :||September 2005|
|Study Completion Date :||June 2007|
- Ongoing pregnancy per embryo transfer
- Biochemical pregnancy per embryo transfer
- Clinical pregnancy per embryo transfer
- Embryological data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417183
|Contact: Tryfon Lainas, PhDemail@example.com|
|Athens, Greece, 11528|
|Contact: Tryfon Lainas, PhD 00302107236333 firstname.lastname@example.org|
|Principal Investigator:||Tryfon Lainas, PhD||Eugonia|